Urovant Sciences (NASDAQ:UROV) released its quarterly earnings data on Tuesday. The company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.15) by $0.30, Fidelity Earnings reports.
Shares of UROV stock traded down $0.21 on Friday, hitting $9.75. The company’s stock had a trading volume of 3,781 shares, compared to its average volume of 82,328. The company has a debt-to-equity ratio of 0.29, a current ratio of 6.20 and a quick ratio of 6.20. Urovant Sciences has a fifty-two week low of $4.05 and a fifty-two week high of $14.49. The firm’s fifty day moving average price is $9.64 and its 200-day moving average price is $8.56. The stock has a market capitalization of $293.09 million, a price-to-earnings ratio of -2.20 and a beta of 1.66.
Several equities research analysts recently issued reports on UROV shares. ValuEngine lowered shares of Urovant Sciences from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. Zacks Investment Research lowered shares of Urovant Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday. Finally, HC Wainwright set a $28.00 price objective on shares of Urovant Sciences and gave the company a “buy” rating in a research note on Monday, October 21st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. Urovant Sciences currently has an average rating of “Hold” and a consensus target price of $21.44.
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.
Further Reading: What is an economic bubble?
Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.